La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Helix BioPharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Helix BioPharma..

Helix BioPharma (OTC:HBPCF) Azioni, Catena delle Opzioni

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

HELIX BIOPHARMA CORP by Helix Biopharma Corp.

Helix BioPharma Corp

WIIM

Tapestry shares are trading higher after the company reported better-than-expected Q1 financial results.

SPCE

Virgin Galactic shares are trading lower. The company announced a $300 million stock sale.

Earnings

Earnings Beats

Earnings Misses

News

SCSC

ScanSource Q1 2025 Adj. EPS $0.84 Beats $0.77 Estimate, Sales $775.580M Miss $783.167M Estimate

Macro Economic Events

Econ #s

Economics

US Continuing Jobless Claims 1.892M vs 1.88M Est.; Prior 1.853M

Initial Jobless Claims 221K Vs 223K Est.; 218K Prior

Telsey Advisory Group analyst Cristina Fernandez maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Market Perform and maintains $8 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Under Armour, Maintains $8 Price Target

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.
Shares of CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/COMM/earnings">third-quarter financial results</a>.
CommScope posted a quarterly loss of 5 cents per share, compared to market estimates of 31 cents per share. The company posted sales of $1.082 billion versus expectations of $1.422 billion.
CommScope shares dipped 47.5% to $3.65 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) shares tumbled 41.1% to $1.91 in pre-market trading after reporting downbeat quarterly results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares fell 24.5% to $10.35 in pre-market trading after the company reported third-quarter financial results.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) declined 19% to $11.89 in pre-market trading following third-quarter results.</li>
<li>Corsair Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSR#NASDAQ">CRSR</a>) fell 14.1% to $6.12 in today's pre-market trading after the company reported worse-than-expected financial results.</li>
<li>Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) fell 12.8% to $33.00 in pre-market trading following mixed third-quarter financial results.</li>
<li>Krispy Kreme, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>) fell 12.6% to $10.85 in pre-market trading after the company reported worse-than-expected third-quarter EPS and sales.</li>
<li>Burford Capital Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) dipped 12.1% to $12.85 in pre-market trading after gaining 6% on Wednesday.</li>
<li>MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) shares dipped 8.6% to $1,936.13 in pre-market trading following third-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

APPS

COMM

CRSR

DNUT

MELI

MTCH

SEDG

WOLF

CommScope Holding Posts Downbeat Results, Joins Match Group, Krispy Kreme And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

USA Unit Labor Costs (QoQ) (Q3) 1.9% Vs 1.1% Est.; 2.4% Prior

Nonfarm Productivity (QoQ) (Q3) 2.2% vs 2.6% Est.

Superior Industries International shares are trading lower after the company reported worse-than-expected Q3 financial results and cut its FY24 net sales outlook below estimates.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/11/06/final-trades-taiwan-semi-palo-alto-charter-comm-and-the-xlf.html">Halftime Report Final Trades</a>,&#8221; Stephen Weiss of Short Hills Capital Partners picked Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/news/24/11/41742360/tsmc-faces-operational-challenges-with-high-electricity-cost-as-taiwan-grapples-with-energy-supply-i">as his final trade.</a>
Amid Taiwan's ongoing energy transition, Taiwan Semiconductor Manufacturing is grappling with escalating electricity costs, which are significantly impacting its operations.
Jason Snipe of Odyssey Capital Advisors said he likes Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), which has a lot of momentum in their new go-to-market strategy.
Palo Alto Networks will release the financial results for its fiscal first quarter 2025, ended Oct. 31, after the closing bell on Wednesday, Nov. 20. Analysts expect the company to report quarterly earnings at $1.48 per share on revenue of $2.12 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kari Firestone of Aureus Asset Management said Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) reported a lower capex than expected.
On Nov. 1, Charter Communications reported fiscal third-quarter 2024 revenue growth of 1.6% year-on-year to $13.8 billion, beating the analyst consensus estimate of $13.7 billion.
Joseph M. Terranova of Virtus Investment Partners named The Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) as his final trade.
Price Action:
<ul>
<li>Taiwan Semiconductor Manufacturing shares fell 1.3% to close at $193.22 during Wednesday's session.</li>
<li>Palo Alto shares rose 5.2% to settle at $385.18 during Wednesday's session.</li>
<li>Charter Communications shares gained 6.7% to close at $408.02 on Wednesday.</li>
<li>The Financial Select Sector SPDR Fund gained 6.1% during Thursday's session.</li>
</ul>
Check This Out:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>
Image: Shutterstock

CHTR

PANW

Palo Alto, Taiwan Semiconductor Manufacturing, Charter Communications And More On CNBC's 'Final Trades'

Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(3.35) by 85.67 percent.

APVO

Aptevo Therapeutics Q3 2024 GAAP EPS $(0.48) Beats $(3.35) Estimate

Maxim Group analyst Jason McCarthy initiates coverage on Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy rating and announces Price Target of $6.

Initiation

QNCX

Maxim Group Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $6

SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) shares are trading lower after the company reported third-quarter results yesterday. Revenues were $260.9 million, <a href="https://www.benzinga.com//node/41786579">missing the consensus of $269.38 million.</a>
Revenues from the solar segment were&nbsp;$247.5 million, up&nbsp;3%&nbsp;from&nbsp;$241.2 million&nbsp;in the prior quarter and down&nbsp;63%&nbsp;from&nbsp;$676.9 million&nbsp;in the same period last year.
The company shipped&nbsp;850 Megawatts (AC) of inverters and 189 MWh of batteries for PV applications in the quarter.
Adjusted gross margin&nbsp;was negative 265.4% versus a&nbsp;positive margin of&nbsp;0.2%&nbsp;in the prior quarter and compared to&nbsp;20.8%&nbsp;last year.
Adjusted operating loss stood at&nbsp;$808.1&nbsp;million versus an adjusted operating loss of&nbsp;$114.3&nbsp;million&nbsp;last quarter.
Adjusted loss per share of $15.33 may not be comparable to <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus loss of $1.63</a>.
Operating cash flow was negative&nbsp;$63.9&nbsp;million in the quarter. As of September 30, cash, cash equivalents, bank deposits, restricted bank deposits, and marketable securities&nbsp;totaled&nbsp;$53.3&nbsp;million.
In the third quarter, SolarEdge conducted an asset valuation review, which resulted in a $1.03 billion write-down and impairment of various assets.
Outlook: For&nbsp;the&nbsp;fourth quarter, the company expects revenue of&nbsp;$180&nbsp;million &#8211; $200 million (versus&nbsp;consensus of&nbsp;$308.66 million), revenues from the solar segment of&nbsp;$170&nbsp;million &#8211; $190 million, and adjusted gross <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">margin of&nbsp;negative&nbsp;4%&nbsp;&#8211;&nbsp;0%</a>.
Investors can gain exposure to the stock via&nbsp;Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>).
Price Action: SEDG shares are down&nbsp;17.3% at $12.13 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41799600" target="_blank" rel="noreferrer noopener">Nvidia Partners With AI Startup Hugging Face To Supercharge Open Source Robotics</a></li>
</ul>

Equities

Large Cap

Guidance

SolarEdge's Tough Q3: Revenue Miss, Multi-Billion Impairment, Bleak Forecast & More

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Buy and maintains $120 price target.

Reiteration

PRAX

HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $120 Price Target

Laird Superfood shares are trading higher after the company reported better-than-expected Q3 financial results.

Needham analyst James Ricchiuti maintains Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) with a Buy and raises the price target from $24 to $26.

FARO

Needham Maintains Buy on Faro Technologies, Raises Price Target to $26

STLA

Infineon And Stellantis Partner To Develop Advanced Power Architecture For Next-Gen EVs, Signing Agreements For PROFET Power Switches And SiC Semiconductors To Enhance Efficiency, Range, And Cost-Effectiveness

ENSC

Ensysce Biosciences shares are trading higher after the company announced it received notice that it may continue its listing on the Nasdaq capital market.

Biotech

General

LUCD

Lucid Diagnostics' ESOGUARD BE-1 Clinical Validation Study On EsoGuard Precancer Testing Accepted For Publication, Strengthening Medicare Coverage Submission

Helix Biopharma GAAP EPS of -$0.01

HBPCF

Helix BioPharma

Comments

Helix BioPharma

Helix BioPharma (HBPCF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO